Chris Cooley
Stock Analyst
(1.94)
# 4,648
Out of 4,648 analysts
57
Total ratings
70%
Success rate
45.43%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $44.37 | -5.34% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $210.78 | +77.91% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $104.86 | +9.67% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $92.17 | -0.18% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $15.19 | -21.00% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $17.07 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $46.76 | +92.47% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $225.82 | +19.56% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $131.38 | -48.24% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $19.21 | +134.25% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $207.33 | +32.64% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $29.14 | +26.97% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $69.70 | -13.92% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $15 | $0.56 | +2,588.17% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $84.72 | -58.69% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $237.44 | -65.89% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $44.37
Upside: -5.34%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $210.78
Upside: +77.91%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $104.86
Upside: +9.67%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $92.17
Upside: -0.18%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $15.19
Upside: -21.00%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $17.07
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $46.76
Upside: +92.47%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $225.82
Upside: +19.56%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $131.38
Upside: -48.24%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $19.21
Upside: +134.25%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $207.33
Upside: +32.64%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $29.14
Upside: +26.97%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $69.70
Upside: -13.92%
Mar 23, 2020
Maintains: Overweight
Price Target: $45 → $15
Current: $0.56
Upside: +2,588.17%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $84.72
Upside: -58.69%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $237.44
Upside: -65.89%